Innovative, life-saving research is key to ending colorectal cancer in our lifetime. Yet CRC does not receive the funding or attention it deserves relative to its devastating impact. The Alliance is changing that.
The Alliance is committed to providing $30 million in research funding for colorectal cancer by 2026. Our voice as advocacy leaders pushing for advancements in knowledge and our own investments in science and research/node/15 will lead to improved patient outcomes and the reality of defeating the disease.
During the past several years, through your generosity, the Alliance’s Chris4Life Research Program has funded fifteen research projects that explored various aspects of colorectal cancer screening, diagnosis, and treatment. Two of our other programs help patients determine and find new avenues for treatment even as their disease progresses.
Funding through the Chris4Life Research Program supported a study led by Dr. Megan Hitchins, based at Cedars-Sinai Hospital in Los Angeles. Her research seeks to identify an accurate and inexpensive blood-based colorectal cancer screening test effective for younger patients.
She and her team developed a test that has positively identified the few patients in their study who were diagnosed with precancerous adenomas–a benign tumor–an encouraging sign that the screening is sensitive enough and therefore, effective, for early colorectal cancer detection. Your support allowed Dr. Hitchins to make this heartening discovery and to leverage the $150,000 grant she received from the Alliance into more than $3 million in funding from the National Institutes of Health to continue and expand her research toward discovery of the test.
Read updates about Dr. Hitchins’ study and other Alliance-funded projects from 2021.
Additionally, through your contributions, we revised our research strategy, updated our priorities, and awarded seven new research grants in December of 2022.
Each of these exciting initiatives focus on one of the following categories of our research priorities:
Thanks to your donations, the Alliance has partnered with Perthera, a leading precision oncology company, to improve access to the best treatment planning for all Stage III and IV colorectal cancer patients.
Powered by artificial intelligence and informed by a patient’s biomarkers and medical history, the service generates personalized treatment recommendations for the patient to discuss with their medical team.
The program simplifies a difficult, confusing, and disheartening search and provides expert-recommended treatment plans to lead patients to their best outcomes and in many cases, save their lives.
The success and speed of clinical trials is critical to bringing new treatments to market and allowing patients to explore additional treatment options. Often trial participation is the only option for extending survival. Yet searching for available trials - and then actually qualifying and accessing the site - can be complicated and overwhelming.
Because of supporters like you, the Alliance offers a seamless trial search and support process. With our live navigation and easy-to-use clinical trial finder tool on our website and in our BlueHQ patient platform, users will receive a list matched exactly to their cancer profile and preferences. Coupled with investment in community partnerships to support trial access, and a 2023 marketing campaign to dispel myths, increase awareness, and build trust around trials, the Alliance is investing in a multi-pronged approach to ensure we identify new treatments faster by solving the challenge of clinical trial access, trust, and participation.
Find a clinical trial near you.
Janice Johnson’s story started with a stomach ache she thought was food poisoning. She was initially dismissed from the ER, but returned when her doctor found something concerning. She received a colonoscopy that revealed stage IIIb colon cancer, which later became metastatic.
Janice connected with the Alliance, and thanks to your support, she’s learned how research developments can help her path toward survivorship.
Janice received biomarker testing, a relatively new research discovery, which identified the genetic makeup of her cancer — information that could lead to scientific insights for better treatment of her specific cancer’s profile.
Your commitment to the Alliance provides information and guidance like this, which gives hope to patients like Janice.
The Colorectal Cancer Alliance’s national Blue Hope Bash, held November 2 at the National Building Museum in Washington, D.C., raised nearly $2 million to support lifesaving work.
Colorectal cancer patient Mark Bassett won a Porsche in the Blue Hope Bash car raffle, bringing unexpected joy and new experiences amid his cancer journey.
A new report reveals how 340B program abuse fails low-income patients, increases the federal deficit, and raises employer health plan costs. Congress must act to fix 340B.
